DK1225870T3 - Sammensætning og fremgangsmåde til cancerantigenimmunterapi - Google Patents

Sammensætning og fremgangsmåde til cancerantigenimmunterapi

Info

Publication number
DK1225870T3
DK1225870T3 DK00968692T DK00968692T DK1225870T3 DK 1225870 T3 DK1225870 T3 DK 1225870T3 DK 00968692 T DK00968692 T DK 00968692T DK 00968692 T DK00968692 T DK 00968692T DK 1225870 T3 DK1225870 T3 DK 1225870T3
Authority
DK
Denmark
Prior art keywords
patient
lymphocytes
composition
effector
cancer antigen
Prior art date
Application number
DK00968692T
Other languages
English (en)
Inventor
Gary W Wood
Original Assignee
Tvax Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tvax Biomedical Llc filed Critical Tvax Biomedical Llc
Application granted granted Critical
Publication of DK1225870T3 publication Critical patent/DK1225870T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00968692T 1999-10-05 2000-10-05 Sammensætning og fremgangsmåde til cancerantigenimmunterapi DK1225870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/412,681 US6406699B1 (en) 1999-10-05 1999-10-05 Composition and method of cancer antigen immunotherapy
PCT/US2000/027399 WO2001024771A1 (en) 1999-10-05 2000-10-05 Composition and method of cancer antigen immunotherapy

Publications (1)

Publication Number Publication Date
DK1225870T3 true DK1225870T3 (da) 2007-05-07

Family

ID=23634000

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00968692T DK1225870T3 (da) 1999-10-05 2000-10-05 Sammensætning og fremgangsmåde til cancerantigenimmunterapi

Country Status (11)

Country Link
US (2) US6406699B1 (da)
EP (1) EP1225870B1 (da)
AT (1) ATE349198T1 (da)
AU (1) AU7856700A (da)
CA (1) CA2388221C (da)
CY (1) CY1106400T1 (da)
DE (1) DE60032622T2 (da)
DK (1) DK1225870T3 (da)
ES (1) ES2279772T3 (da)
PT (1) PT1225870E (da)
WO (1) WO2001024771A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531396A (ja) * 1998-12-02 2002-09-24 ファイザー・プロダクツ・インク ｐ５３ファミリーのタンパク質の配座安定性を回復するための方法及び組成物
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20020168351A1 (en) * 2000-10-20 2002-11-14 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
WO2002034119A2 (en) 2000-10-27 2002-05-02 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US6844000B2 (en) 2001-12-07 2005-01-18 Bayer Pharmaceuticals Corporation Use of Parapox B2L protein to treat cancer and modify immune responses
JP2006507214A (ja) * 2002-02-22 2006-03-02 イントラセル・リソーシーズ・エル・エル・シー 無菌の、免疫原性の、非腫瘍形成性の腫瘍細胞組成物及び方法
WO2003077864A2 (en) * 2002-03-15 2003-09-25 Department Of Veterans Affairs, Rehabilitation R & D Service Methods and compositions for directing cells to target organs
US20040151704A1 (en) * 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2004258799A1 (en) * 2003-02-21 2005-02-03 Hasumi Llc (Dba Shukokai International) Human lymphocyte vaccine adjuvant
EP2234642B8 (en) 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Method of increasing immunological effect
WO2010104836A1 (en) * 2009-03-09 2010-09-16 Tvax Biomedical, Llc Infectious disease cellular immunotherapy
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP6257655B2 (ja) 2013-03-01 2018-01-10 アメリカ合衆国 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
EP4218778A3 (en) 2015-05-28 2023-08-23 Kite Pharma, Inc. Diagnostic methods for t cell therapy
KR20230147769A (ko) 2015-05-28 2023-10-23 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
EP3347473A4 (en) * 2015-09-09 2019-04-10 Tvax Biomedical I, LLC METHODS FOR COMBINING ADOPTIVE TRANSFER THERAPY OF T-CELLS WITH ONCOLYTIC VIRUS ADHERENCE THERAPY
JP6952029B2 (ja) 2015-10-20 2021-10-20 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｔ細胞療法用のｔ細胞を調製する方法
US11781112B2 (en) * 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
MA43603A1 (fr) 2016-04-01 2019-03-29 Amgen Inc Récepteurs chimériques et leurs procédés d'utilisation
IL303785A (en) 2016-04-01 2023-08-01 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use
WO2018106958A1 (en) * 2016-12-07 2018-06-14 Transtarget, Inc. Methods and compositions for vaccinating and boosting cancer patients
PT3583129T (pt) 2017-02-14 2021-12-14 Kite Pharma Inc Moléculas de ligação a cd70 e seus métodos de uso
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
SG11201907744QA (en) 2017-04-01 2019-09-27 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
US11357796B2 (en) 2017-04-03 2022-06-14 Kite Pharma, Inc. Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CN110662831A (zh) 2017-05-26 2020-01-07 凯德药业股份有限公司 制备和使用胚胎间充质祖细胞的方法
SG11202002327PA (en) * 2017-09-15 2020-04-29 Kite Pharma Inc Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
AU2018338192B2 (en) 2017-09-22 2022-03-03 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
AU2018351046A1 (en) 2017-10-18 2020-04-30 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
MX2020007543A (es) 2018-01-15 2020-09-09 Pfizer Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb.
US20200390814A1 (en) 2018-02-02 2020-12-17 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
KR102618231B1 (ko) 2018-02-16 2023-12-28 카이트 파마 인코포레이티드 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
SG11202009881WA (en) 2018-04-12 2020-11-27 Kite Pharma Inc Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
CN112512537A (zh) 2018-06-01 2021-03-16 凯德药业股份有限公司 嵌合抗原受体t细胞疗法
EP3810780A1 (en) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
EP3830125A1 (en) 2018-08-02 2021-06-09 Kite Pharma, Inc. Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2020112672A1 (en) * 2018-11-26 2020-06-04 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of cancer cell response to ml329 or a derivative thereof
WO2020113098A1 (en) 2018-11-29 2020-06-04 Vineti Inc. Centralized and decentralized individualized medicine platform
CA3177829A1 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
TW202108150A (zh) 2019-05-03 2021-03-01 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
CN114391021A (zh) 2019-06-21 2022-04-22 凯德药业股份有限公司 TGF-β受体和使用方法
CN114341348A (zh) 2019-09-03 2022-04-12 艾洛基治疗公司 制备用于t细胞疗法的t细胞的方法
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CN116113689A (zh) 2020-08-14 2023-05-12 凯德药业股份有限公司 改善免疫细胞功能
US20220064596A1 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
AU2021369507A1 (en) 2020-10-28 2023-06-01 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
EP4267623A1 (en) 2020-12-24 2023-11-01 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
EP4275044A1 (en) 2021-01-10 2023-11-15 Kite Pharma, Inc. T cell therapy
WO2022178243A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
IL305571A (en) 2021-03-11 2023-10-01 Kite Pharma Inc Improving the function of immune system cells
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
JP2024514624A (ja) 2021-04-16 2024-04-02 カイト ファーマ インコーポレイテッド Ｔａｃｉ／ｂｃｍａ二重結合分子
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
IL308696A (en) 2021-05-24 2024-01-01 Kite Pharma Inc NKG2D-based chemical antigen receptor
US20230020993A1 (en) 2021-06-08 2023-01-19 Kite Pharma, Inc. Gpc3 binding molecules
EP4363558A1 (en) 2021-07-01 2024-05-08 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
CN117597738A (zh) 2021-07-02 2024-02-23 凯德药业股份有限公司 一种鉴定来自用于细胞治疗应用的基因构建体的基因产物中的变体的方法
WO2023009989A1 (en) 2021-07-26 2023-02-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
TW202313665A (zh) 2021-07-30 2023-04-01 美商凱特製藥公司 細胞療法誘導之毒性的監測及管理
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform
AR127745A1 (es) 2021-10-18 2024-02-28 Kite Pharma Inc Dominios de señalización para receptores quiméricos de antígenos
WO2023159001A1 (en) 2022-02-15 2023-08-24 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2024044670A1 (en) 2022-08-26 2024-02-29 Kite Pharma, Inc. Improving immune cell function
US20240158869A1 (en) 2022-10-28 2024-05-16 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024092152A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Improving efficacy and durable response of immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US5725855A (en) 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
EP0852618A1 (en) * 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease

Also Published As

Publication number Publication date
AU7856700A (en) 2001-05-10
EP1225870A1 (en) 2002-07-31
DE60032622D1 (de) 2007-02-08
US20020006409A1 (en) 2002-01-17
EP1225870A4 (en) 2003-05-28
CY1106400T1 (el) 2011-10-12
ES2279772T3 (es) 2007-09-01
ATE349198T1 (de) 2007-01-15
PT1225870E (pt) 2007-06-11
EP1225870B1 (en) 2006-12-27
CA2388221C (en) 2007-12-04
US6406699B1 (en) 2002-06-18
CA2388221A1 (en) 2001-04-12
DE60032622T2 (de) 2007-12-20
WO2001024771A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
Davis An overview of cancer immunotherapy
WO2002034205A3 (en) Using heat shock proteins to increase immune response
HK1024268A1 (en) Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same.
ES2113980T3 (es) Ligandos solubles para cd40.
NO20015073L (no) Vaksiner
ZA91559B (en) Vaccines against cancer and infectious diseases
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
EP0719150A4 (en) CELL VACCINE AND METHODS OF USE IN THE TREATMENT OF SOLID MALIGNANT TUMORS
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
US7402317B2 (en) Anti-cancer vaccine
NO981530D0 (no) Pasientspesifikke immunoadsorpsjonsmidler for utenomkroppslig aferese og fremgangsmåter for fremstilling av immunoadsorpsjonsmidlene
WO2003090687A8 (en) Using heat shock proteins to increase immune response
DE60128070D1 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
MXPA03005030A (es) Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.
Takigawa et al. Percutaneous Peptide Immunization via Corneum Barrier‐disrupted Murine Skin for Experimental Tumor Immunoprophylaxis
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
NO930798L (no) Fremgangsmaate og middel mot tumorer
NZ512850A (en) Treatment of papillomavirus infections
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
MX9604099A (es) Inmunoterapia de cancer con linfocitos alogenicos.
RU2000111634A (ru) Способ комбинированной иммунотерапии злокачественных опухолей головного мозга
Prescott New therapeutic approaches for treating lymphomas
WO2002066053A3 (en) Method of treating or preventing disease characterized by cryptococcus neoformans infection